-
1
المؤلفون: Kapil N. Bhalla, Philipp le Coutre, Richard A. Larson, Giuseppe Saglio, Jorge Cortes-Franco, Hagop M. Kantarjian, Javier Pinilla-Ibarz, Andreas Hochhaus, Yaping Shou, Francis J. Giles, Michele Baccarani, Giovanni Martinelli, Timothy P. Hughes, Oliver G. Ottmann, Dong-Wook Kim, Neil Gallagher, Jim Wang, Jerald P. Radich, Norbert Gattermann
المصدر: Blood. 114:1129-1129
مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Imatinib, Cell Biology, Hematology, Biochemistry, Imatinib resistant, Clinical trial, Imatinib mesylate, Nilotinib, Family medicine, Long term outcomes, Medicine, In patient, Chronic phase CML, business, health care economics and organizations, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::886519fe6d1fdb8ddea6276b4ecf4d9aTest
https://doi.org/10.1182/blood.v114.22.1129.1129Test -
2
المؤلفون: Brian J. Druker, François Guilhot, Eren Demirhan, Dong-Wook Kim, John V. Reynolds, Timothy P. Hughes, Yanfeng Wang, Camille Granvil, Michele Baccarani, Jorge Cortes-Franco, Yu Jin
المصدر: ResearcherID
مصطلحات موضوعية: medicine.medical_specialty, business.industry, medicine.drug_class, Immunology, Imatinib, Cell Biology, Hematology, medicine.disease, Biochemistry, Tyrosine-kinase inhibitor, Cmin, Leukemia, Imatinib mesylate, Tolerability, Internal medicine, medicine, Chronic phase CML, Adverse effect, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014e25c9484c832b21dffc2454174437Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000272725801307&KeyUID=WOS:000272725801307Test